ATLAS

NCT00003016 📎

Regimen

Experimental
Continue tamoxifen 20 mg daily to year 10 (total 10 years).
Control
Stop tamoxifen at year 5 (total 5 years).

Population

Women with ER+ early breast cancer who had completed 5 years of adjuvant tamoxifen, randomized to continue or stop at year 5.

Key finding

ATLAS (with aTTom) established that extending adjuvant tamoxifen from 5 to 10 years further reduces late recurrence and breast cancer mortality in ER+ disease. Supports NCCN BINV-K extended endocrine therapy options for appropriate patients, particularly those not eligible for AI extension.

Source: PMID 23219286

Timeline

  • Publication: 2013 Mar 9

Guideline citations

  • NCCN BREAST